Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE In summary, high grade astrocytomas with BRAF V600E, ATRX, and CDKN2A/B alternations had unique clinicopathological features and may be a novel subset of high grade glioma. 30972500

2019

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE Thus BRAF V600E mutation is common in desmoplastic non-infantile astrocytoma/ganglioglioma, but does not affect the prognosis. 29902580

2018

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE Similar to previously reported findings on E-GBM associated with low-grade glioma, this case suggested that low-grade astrocytic glioma with BRAF V600E mutation progressed to E-GBM. 26602910

2016

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing. 25346165

2015

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE BRAF V600E mutation was observed both in epithelioid tumor cells and in diffusely infiltrating less atypical astrocytoma cells. 24354918

2014

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE The BRAF(V600E) inhibitor PLX4720 significantly increased survival of mice after intracranial transplant of genetically relevant murine or human astrocytoma cells. 22586120

2012

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE With regard to implications for therapy, our results support evaluation of BRAF(V600E)-specific inhibitors for treating BRAF(V600E) MA patients. 22038996

2011

dbSNP: rs121913377
rs121913377
0.080 GeneticVariation BEFREE BRAF(V600E) mutation seems to define a subset of malignant astrocytomas in children, in which there is frequent concomitant homozygous deletion of CDKN2A (five of seven cases). 20068183

2010